You are here

  • Home
  • Archive
  • Volume 15, Issue 2
  • Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA

Citation Tools

Article menu
Download PDFPDF
Therapeutics
Cost-effectiveness analysis
Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Davis WA
Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA
BMJ Evidence-Based Medicine 2010;15:40-41.